Analisis Keuangan Saham LEGN - Legend Biotech Corporation - Depositary Receipt (Common Stock) (NasdaqGS) Stock

Legend Biotech Corporation - Depositary Receipt (Common Stock)
US ˙ NasdaqGS ˙ US52490G1022

Gambaran Umum
Legend Biotech Corporation is a biopharmaceutical company based in Somerset, New Jersey, with a primary focus on the development and commercialization of novel cell therapies for oncology and other indications. As a leader in the biotechnology industry, the company leverages innovative technologies to develop treatments that address unmet medical needs, particularly in the realm of cancer. One of its key projects includes the development of CAR-T therapies, notably their BCMA-targeted CAR-T cell therapy, which has shown promise in treating multiple myeloma, a type of blood cancer. Legend Biotech's commitment to groundbreaking research and therapeutic development places it at the forefront of cellular therapy advancements, striving to enhance patient outcomes in areas with significant therapeutic gaps.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai revenue untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 796.84 MM.
  • Nilai operating income untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -217.84 MM.
  • Nilai net income untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -325.33 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 796.84 -217.84 -325.33
2025-03-31 728.30 -237.93 -218.15
2024-12-31 627.24 -305.15 -177.03
2024-09-30 520.18 -351.24 -348.13
2024-06-30 455.99 -373.41 -285.01
2024-03-31 342.80 -435.75 -465.95
2023-12-31 285.14 -442.22 -518.25
2023-09-30 233.31 -449.75 -509.31
2023-06-30 164.66 -501.94 -532.06
2023-03-31 112.01 -508.41 -517.36
2022-12-31 117.00 -458.05 -446.35
2022-09-30 105.92 -469.64 -416.18
2022-06-30 95.60 -412.13 -456.62
2022-03-31 118.59 -366.31 -346.40
2021-12-31 68.83 -394.02 -403.58
2021-09-30 93.47 -312.94 -355.70
2021-06-30 88.89 -292.25 -296.86
2021-03-31 80.40 -259.73 -340.15
2020-12-31 75.00 -229.87 -266.37
2020-09-30 58.68 -227.28 -309.59
2020-06-30
2020-03-31
Laporan Laba Rugi: EPS
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30 -1.91 -1.92
2024-06-30 -1.57 -1.56
2024-03-31 -2.58 -2.57
2023-12-31 -2.94 -2.94
2023-09-30 -2.96 -2.95
2023-06-30 -3.19 -3.17
2023-03-31 -3.20 -3.19
2022-12-31 -2.81 -2.80
2022-09-30 -2.69 -2.69
2022-06-30 -3.04 -3.04
2022-03-31 -2.37 -2.37
2021-12-31 -2.87 -2.86
2021-09-30 -2.59 -2.58
2021-06-30 -2.21 -2.21
2021-03-31 -2.69 -2.68
2020-12-31 -2.25 -2.26
2020-09-30 -2.81 -2.80
2020-06-30 -2.66 -2.64
2020-03-31 -1.65 -1.65
Arus Kas: Operasi, Investasi, Pendanaan
  • Nilai cash from operating activities untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -274.70 MM.
  • Nilai cash from investing activities untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 332.35 MM.
  • Nilai kas dari aktivitas pendanaan untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 3.59 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30 -274.70 332.35 3.59
2025-03-31 -263.31 -197.76 5.53
2024-12-31 -144.03 -850.54 5.70
2024-09-30 -157.60 -355.19 6.96
2024-06-30 -142.63 -893.34 3.67
2024-03-31 -238.54 -319.39 792.76
2023-12-31 -393.28 92.79 791.49
2023-09-30 -347.37 -289.79 789.78
2023-06-30 -358.64 47.17 1,166.55
2023-03-31 -261.81 171.44 377.51
2022-12-31 -201.28 -77.09 377.98
2022-09-30 -221.09 -5.51 702.32
2022-06-30 -193.57 -239.07 325.74
2022-03-31 -250.37 -410.33 626.48
2021-12-31 -198.47 -194.98 626.66
2021-09-30 -184.87 -230.33 303.76
2021-06-30 -204.65 -183.28 312.28
2021-03-31 -204.00 -23.82 470.33
2020-12-31 -223.00 -24.17 618.88
2020-09-30 -227.04 28.12 611.54
2020-06-30
2020-03-31
Metrik Penilaian: PE, PriceToBook, PriceToTBV
  • p/e untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -29.94.
  • p/libro untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 6.42.
  • p/tbv untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 6.43.
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30 -29.94 6.42 6.43
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31 -18.12 10.87
2022-12-31
2022-09-30 15.59 15.75
2022-06-30 -24.52 19.37 19.57
2022-03-31 -14.48 11.87 11.99
2021-12-31 -20.16 31.75 32.54
2021-09-30 -22.60 19.74 20.01
2021-06-30
2021-03-31 -17.99 29.64 30.23
2020-12-31 -20.16 21.83 22.06
2020-09-30 -19.71 18.22 18.28
2020-06-30 -22.53 15.22 15.25
2020-03-31
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
  • EBIT/EV untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.03.
  • EBIT (3 tahun) / EV untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.05.
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30 -0.03 -0.05
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31 -0.06 -0.05
2022-12-31 0.00 -0.03
2022-09-30 -0.05 -0.05
2022-06-30 -0.04 -0.04
2022-03-31 -0.08 -0.06
2021-12-31 -0.05 -0.04
2021-09-30 -0.05 -0.03
2021-06-30
2021-03-31 -0.06 -0.03
2020-12-31 -0.05 -0.03
2020-09-30 -0.05 -0.02
2020-06-30 -0.05 -0.02
2020-03-31
Efektivitas Manajemen
  • roa untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.12.
  • roe untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.19.
  • roic untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.16.
  • croic untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.33.
  • ocroic untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.19.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2025-06-30 -0.12 -0.19 -0.16 -0.33 -0.19
2025-03-31 -0.10 -0.15 -0.13 -0.71 -0.10
2024-12-31 -0.19 -0.28 -0.24 -0.34 -0.11
2024-09-30 -0.15 -0.21 -0.19 -0.69 -0.10
2024-06-30 -0.39 -0.71 -0.31 0.16 -0.16
2024-03-31 -0.33 0.31 -0.25
2023-12-31 -0.31 0.09 -0.21
2023-09-30 -0.52 -0.95 -0.31 0.49 -0.21
2023-06-30 -0.51 -0.94 -0.31 0.50 -0.21
2023-03-31 -0.43 -1.02 -0.55 0.29 -0.27
2022-12-31 0.00 0.00
2022-09-30 -0.43 -1.53 -0.47 0.53 -0.25
2022-06-30 -0.40 -1.02 -0.66 -0.16 -0.28
2022-03-31 -0.63 -1.87 -0.62 -0.06 -0.45
2021-12-31 -0.49 -1.27 -0.71 0.43 -0.62
2021-09-30 -0.50 -0.89 -1.45 -0.45 -0.57
2021-06-30 -0.38 -0.74 -0.82 -0.21 -0.57
2021-03-31 -0.93 -1.62 1.16 -0.97
2020-12-31 -1.05 -1.07 1.31 -0.79
2020-09-30 -35.80 -0.63 0.84 -0.46
2020-06-30 -0.63 -31.32 -0.49 0.95 -0.26
2020-03-31 -0.38 -19.05
Gross Margins
  • marjin kotor untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.09.
  • marjin bersih untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.30.
  • marjin operasi untuk Legend Biotech Corporation - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.33.
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2025-06-30 0.09 -0.30 -0.33
2025-03-31 -0.03 -0.28 -0.49
2024-12-31 -0.17 -0.67 -0.68
2024-09-30 -0.31 -0.63 -0.82
2024-06-30 -0.64 -1.36 -1.27
2024-03-31 -0.85 -1.82 -1.55
2023-12-31 -1.11 -2.18 -1.93
2023-09-30 -1.93 -3.23 -3.05
2023-06-30 -3.23 -3.23 -3.05
2023-03-31 0.44 -5.09 -5.00
2022-12-31
2022-09-30 1.00 -3.93 -4.43
2022-06-30 1.00 -4.69 -4.00
2022-03-31 1.00 -2.91 -3.07
2021-12-31 1.00 -4.16 -3.98
2021-09-30 1.00 -3.88 -3.44
2021-06-30 1.00 -3.34 -3.29
2021-03-31 1.00 -4.23 -3.23
2020-12-31 1.00 -3.71 -2.73
2020-09-30 1.00 -5.53 -4.10
2020-06-30 1.00 -4.37 -3.09
2020-03-31 1.00 -2.68 -2.70
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)1801198
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations
Other Listings
DE:9LB € 30.80
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista